Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FASN | P49327 | 9/20 | 0.82 |
| ▸ | MELK | Q14680 | 1/20 | 0.49 |
| ▸ | ACACB | O00763 | 5/20 | 0.41 |
| ▸ | ACACA | Q13085 | 5/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.39 |
| ▸ | GHSR | Q92847 | 1/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22220719 | 0.90 | FASN (1.00) | FASNMELKACACBACACA | |
| SCHEMBL22220832 | 0.90 | FASN (0.78) | FASNMELKACACBACACAABL1 | |
| SCHEMBL22220845 | 0.84 | FASN (0.89) | FASNMELKGHSR | |
| SCHEMBL22220831 | 0.84 | FASN (0.68) | FASNMELKACACBACACAGHSR | |
| SCHEMBL22220786 | 0.83 | FASN (0.58) | FASNMELK | |
| SCHEMBL22220863 | 0.83 | FASN (0.65) | FASNMELKACACBACACAABL1 | |
| SCHEMBL22220818 | 0.82 | FASN (0.57) | FASN | |
| SCHEMBL22220858 | 0.82 | FASN (0.56) | FASN | |
| SCHEMBL14731385 | 0.81 | FASN (0.56) | FASN | |
| SCHEMBL14731369 | 0.81 | FASN (0.64) | FASNMELKACACBACACAABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020150423-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | YUMANITY THERAPEUTICS, INC. (US) | 2020-07-23 | — | — | WO | disclosed |
| US-20200222400-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2020-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200222400-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | NLN, CLN6, OTC | FASN 2790/4885MELK 3492/4885ACACB 502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.